Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Epigenetic Test Could Determine Efficacy of New Immunotherapy Treatments Against Multiple Myeloma

By LabMedica International staff writers
Posted on 11 Oct 2024

Multiple myeloma is a blood cancer that primarily affects individuals over the age of sixty, and its occurrence rises as the population ages. More...

In this disease, the bone marrow—the spongy tissue inside bones that produces normal blood cells—becomes overrun by abnormal plasma cells. Under normal conditions, plasma cells are part of the immune system, helping to fight infections, but in multiple myeloma, they become malignant, damaging the bone marrow and spreading to other areas such as the spine, skull, pelvis, and ribs. While current treatments can manage the disease for extended periods, a definitive cure remains elusive. However, advancements in immunotherapy, including the use of antibodies and engineered immune cells, have opened new possibilities for treating patients who relapse or are resistant to standard therapies.

Now, researchers at Josep Carreras Leukemia Research Institute (IJC, Barcelona, Spain) have demonstrated an epigenetic test that predicts the effectiveness of new immunotherapy treatments for multiple myeloma. In a study published in Leukemia, a journal from the Nature group, the team focused on identifying genes altered in cancer that are involved in immune system function and antigen recognition. This led them to discover a subgroup of multiple myeloma patients with an epigenetic modification in the PVR gene, a key immune system regulator, which resulted in the gene losing its activity.

The researchers observed that patients with this PVR gene defect experienced a better disease progression, leading them to hypothesize that cancer cells in these individuals might be more susceptible to immune system attacks. To test this idea, they used a cellular model of multiple myeloma, eliminating the PVR gene to observe how the cells responded to various immunotherapy approaches, including antibodies, T-lymphocytes, and genetically engineered natural killer cells (CAR-T cells). In all instances, the immune response effectively targeted and attacked the tumor cells in vitro. This discovery could help clinicians identify which patients are likely to benefit most from immunotherapy, improving personalized treatment strategies and clinical management.

“Our results demonstrate that in this malignant blood disease, inhibiting the PVR gene decisively increases the probability of success of immunotherapy,” said Dr. Manel Esteller, ICREA Research Professor at IJC, who directed the research “Now, then, it would be the turn of the pharmaceutical industry and clinical research to bring these results to the bedside of the patient."

Related Links:
IJC


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.